 Casey Greene
Concepts (416)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Computational Biology | 32 | 2025 | 644 | 5.790 |
Why?
| | Gene Expression Profiling | 23 | 2025 | 1774 | 4.090 |
Why?
| | Software | 17 | 2025 | 665 | 3.000 |
Why?
| | Machine Learning | 18 | 2024 | 493 | 2.940 |
Why?
| | Single-Cell Analysis | 8 | 2025 | 313 | 2.920 |
Why?
| | Genomics | 18 | 2025 | 795 | 2.670 |
Why?
| | Transcriptome | 20 | 2024 | 971 | 2.570 |
Why?
| | Algorithms | 18 | 2025 | 1704 | 2.270 |
Why?
| | Gene Regulatory Networks | 10 | 2024 | 305 | 2.250 |
Why?
| | Information Dissemination | 6 | 2020 | 218 | 2.220 |
Why?
| | Epistasis, Genetic | 6 | 2023 | 70 | 1.700 |
Why?
| | Sequence Analysis, RNA | 8 | 2025 | 452 | 1.630 |
Why?
| | Biomedical Research | 5 | 2025 | 692 | 1.600 |
Why?
| | Data Mining | 5 | 2018 | 116 | 1.600 |
Why?
| | Pseudomonas aeruginosa | 7 | 2024 | 352 | 1.590 |
Why?
| | Neoplasms | 12 | 2022 | 2671 | 1.560 |
Why?
| | Ovarian Neoplasms | 9 | 2025 | 565 | 1.530 |
Why?
| | Viral Vaccines | 2 | 2023 | 98 | 1.490 |
Why?
| | Rare Diseases | 2 | 2023 | 104 | 1.360 |
Why?
| | Databases, Genetic | 13 | 2022 | 237 | 1.330 |
Why?
| | Gene Expression | 4 | 2023 | 1502 | 1.140 |
Why?
| | Research Personnel | 2 | 2020 | 173 | 1.100 |
Why?
| | Genome-Wide Association Study | 10 | 2021 | 1431 | 1.060 |
Why?
| | Humans | 104 | 2025 | 137585 | 0.950 |
Why?
| | Natural Language Processing | 2 | 2024 | 95 | 0.940 |
Why?
| | Artificial Intelligence | 4 | 2024 | 279 | 0.940 |
Why?
| | Peer Review, Research | 2 | 2022 | 43 | 0.910 |
Why?
| | Nonlinear Dynamics | 2 | 2023 | 88 | 0.910 |
Why?
| | Journalism | 1 | 2024 | 7 | 0.880 |
Why?
| | Direct-To-Consumer Screening and Testing | 1 | 2024 | 1 | 0.880 |
Why?
| | Breeding | 1 | 2024 | 64 | 0.860 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2023 | 31 | 0.830 |
Why?
| | Cystadenocarcinoma, Serous | 4 | 2025 | 77 | 0.780 |
Why?
| | User-Computer Interface | 4 | 2023 | 159 | 0.750 |
Why?
| | Societies, Scientific | 1 | 2021 | 51 | 0.720 |
Why?
| | Genetic Testing | 1 | 2024 | 460 | 0.690 |
Why?
| | Neurofibromin 1 | 2 | 2019 | 26 | 0.690 |
Why?
| | Metadata | 1 | 2020 | 14 | 0.680 |
Why?
| | Data Compression | 1 | 2020 | 5 | 0.670 |
Why?
| | Guidelines as Topic | 1 | 2022 | 275 | 0.640 |
Why?
| | Computer Simulation | 7 | 2025 | 978 | 0.630 |
Why?
| | Computer Security | 1 | 2019 | 23 | 0.620 |
Why?
| | Genetic Association Studies | 3 | 2016 | 377 | 0.620 |
Why?
| | Precision Medicine | 5 | 2024 | 429 | 0.610 |
Why?
| | Confidentiality | 1 | 2019 | 73 | 0.600 |
Why?
| | Language | 1 | 2022 | 292 | 0.600 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 179 | 0.590 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2021 | 539 | 0.590 |
Why?
| | Scholarly Communication | 1 | 2018 | 2 | 0.580 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2025 | 630 | 0.570 |
Why?
| | Databases, Bibliographic | 1 | 2018 | 32 | 0.570 |
Why?
| | ras Proteins | 2 | 2019 | 153 | 0.570 |
Why?
| | Probability | 3 | 2024 | 304 | 0.560 |
Why?
| | Access to Information | 1 | 2018 | 49 | 0.550 |
Why?
| | Biomedical Technology | 1 | 2018 | 43 | 0.550 |
Why?
| | Disease | 3 | 2018 | 98 | 0.540 |
Why?
| | Glioblastoma | 2 | 2019 | 345 | 0.530 |
Why?
| | Gene Silencing | 2 | 2018 | 195 | 0.530 |
Why?
| | alpha-Synuclein | 1 | 2017 | 35 | 0.520 |
Why?
| | Models, Biological | 3 | 2020 | 1783 | 0.520 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 138 | 0.510 |
Why?
| | Parasites | 1 | 2017 | 50 | 0.510 |
Why?
| | Genome, Human | 6 | 2018 | 425 | 0.500 |
Why?
| | Models, Genetic | 5 | 2019 | 600 | 0.490 |
Why?
| | Systems Biology | 3 | 2018 | 67 | 0.490 |
Why?
| | Gene Ontology | 5 | 2020 | 53 | 0.490 |
Why?
| | Workflow | 1 | 2017 | 165 | 0.480 |
Why?
| | MicroRNAs | 1 | 2022 | 692 | 0.480 |
Why?
| | Research | 1 | 2018 | 451 | 0.470 |
Why?
| | Quantitative Trait, Heritable | 1 | 2016 | 125 | 0.470 |
Why?
| | Protein Interaction Maps | 1 | 2015 | 48 | 0.470 |
Why?
| | Unsupervised Machine Learning | 4 | 2024 | 22 | 0.460 |
Why?
| | Neurodegenerative Diseases | 1 | 2017 | 135 | 0.460 |
Why?
| | Bacterial Proteins | 2 | 2020 | 879 | 0.460 |
Why?
| | Internet | 5 | 2023 | 655 | 0.430 |
Why?
| | Tumor Microenvironment | 4 | 2023 | 674 | 0.430 |
Why?
| | Authorship | 2 | 2024 | 53 | 0.420 |
Why?
| | Models, Theoretical | 1 | 2017 | 578 | 0.410 |
Why?
| | Bayes Theorem | 5 | 2018 | 405 | 0.410 |
Why?
| | RNA, Untranslated | 1 | 2014 | 124 | 0.380 |
Why?
| | Cluster Analysis | 3 | 2024 | 499 | 0.360 |
Why?
| | Drosophila melanogaster | 5 | 2019 | 233 | 0.360 |
Why?
| | Microbiota | 2 | 2017 | 762 | 0.360 |
Why?
| | Pandemics | 5 | 2023 | 1639 | 0.360 |
Why?
| | Signal Transduction | 8 | 2020 | 5079 | 0.350 |
Why?
| | Bibliometrics | 2 | 2024 | 63 | 0.350 |
Why?
| | Writing | 2 | 2024 | 95 | 0.340 |
Why?
| | Publishing | 2 | 2024 | 147 | 0.330 |
Why?
| | Databases, Factual | 2 | 2018 | 1357 | 0.320 |
Why?
| | Embryonic Development | 3 | 2020 | 119 | 0.320 |
Why?
| | Molecular Sequence Annotation | 5 | 2023 | 99 | 0.320 |
Why?
| | Terminology as Topic | 3 | 2022 | 216 | 0.320 |
Why?
| | Female | 24 | 2025 | 73304 | 0.300 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2010 | 89 | 0.300 |
Why?
| | Scleroderma, Systemic | 3 | 2017 | 122 | 0.300 |
Why?
| | Supervised Machine Learning | 2 | 2020 | 17 | 0.300 |
Why?
| | Genome | 2 | 2019 | 300 | 0.290 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2021 | 2189 | 0.270 |
Why?
| | Betacoronavirus | 2 | 2020 | 270 | 0.270 |
Why?
| | Animals | 19 | 2025 | 36940 | 0.270 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2021 | 872 | 0.260 |
Why?
| | Drosophila Proteins | 2 | 2019 | 204 | 0.250 |
Why?
| | Homologous Recombination | 1 | 2025 | 28 | 0.240 |
Why?
| | Proteomics | 4 | 2021 | 1111 | 0.240 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 373 | 0.230 |
Why?
| | Coronavirus Infections | 2 | 2020 | 364 | 0.230 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2021 | 289 | 0.230 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 363 | 0.230 |
Why?
| | Publications | 2 | 2022 | 47 | 0.230 |
Why?
| | Reproducibility of Results | 6 | 2021 | 3284 | 0.220 |
Why?
| | Genetic Predisposition to Disease | 5 | 2021 | 2426 | 0.210 |
Why?
| | Sexism | 1 | 2024 | 61 | 0.210 |
Why?
| | Mice | 12 | 2025 | 17787 | 0.210 |
Why?
| | Cystic Fibrosis | 2 | 2024 | 1114 | 0.210 |
Why?
| | Science | 1 | 2024 | 53 | 0.210 |
Why?
| | Breast Neoplasms | 2 | 2015 | 2253 | 0.200 |
Why?
| | Cell Line, Tumor | 4 | 2019 | 3412 | 0.200 |
Why?
| | Causality | 1 | 2023 | 126 | 0.200 |
Why?
| | Vaccines, Subunit | 1 | 2023 | 49 | 0.200 |
Why?
| | Pedigree | 1 | 2024 | 514 | 0.200 |
Why?
| | Dogs | 1 | 2024 | 413 | 0.200 |
Why?
| | Sample Size | 1 | 2022 | 125 | 0.190 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2019 | 252 | 0.190 |
Why?
| | Mushroom Bodies | 2 | 2019 | 4 | 0.190 |
Why?
| | Male | 16 | 2025 | 67762 | 0.190 |
Why?
| | Hedgehog Proteins | 2 | 2021 | 195 | 0.190 |
Why?
| | Pseudomonas Infections | 1 | 2024 | 225 | 0.180 |
Why?
| | Periodicals as Topic | 1 | 2024 | 211 | 0.180 |
Why?
| | Quality Control | 1 | 2021 | 172 | 0.180 |
Why?
| | High-Throughput Screening Assays | 2 | 2014 | 158 | 0.180 |
Why?
| | ADAM10 Protein | 1 | 2021 | 30 | 0.170 |
Why?
| | Neoplasm Grading | 4 | 2025 | 307 | 0.170 |
Why?
| | Cooperative Behavior | 2 | 2021 | 451 | 0.170 |
Why?
| | Bone Development | 1 | 2021 | 54 | 0.170 |
Why?
| | Gamma Rays | 1 | 2021 | 57 | 0.170 |
Why?
| | Electronic Health Records | 3 | 2018 | 1069 | 0.170 |
Why?
| | Fibrosis | 2 | 2021 | 552 | 0.170 |
Why?
| | Pancreatic Neoplasms | 2 | 2021 | 938 | 0.170 |
Why?
| | Linear Models | 1 | 2023 | 849 | 0.170 |
Why?
| | Medical Informatics | 1 | 2021 | 101 | 0.170 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 80 | 0.170 |
Why?
| | Organ Specificity | 3 | 2017 | 305 | 0.170 |
Why?
| | Cystadenoma, Serous | 1 | 2020 | 21 | 0.170 |
Why?
| | Alzheimer Disease | 2 | 2017 | 560 | 0.170 |
Why?
| | Hemerythrin | 1 | 2020 | 1 | 0.170 |
Why?
| | Mutation | 5 | 2025 | 3958 | 0.170 |
Why?
| | Bone Diseases | 1 | 2021 | 62 | 0.170 |
Why?
| | Privacy | 1 | 2020 | 42 | 0.170 |
Why?
| | Histone Code | 1 | 2020 | 34 | 0.160 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2020 | 1396 | 0.160 |
Why?
| | Systems Integration | 2 | 2017 | 37 | 0.160 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 97 | 0.160 |
Why?
| | Radiation Injuries | 1 | 2021 | 145 | 0.160 |
Why?
| | Neurofibromatosis 1 | 1 | 2020 | 52 | 0.160 |
Why?
| | Genetic Fitness | 1 | 2020 | 59 | 0.160 |
Why?
| | Phenotype | 4 | 2021 | 3196 | 0.160 |
Why?
| | Radiosurgery | 1 | 2022 | 344 | 0.160 |
Why?
| | Cerebellar Neoplasms | 1 | 2021 | 152 | 0.150 |
Why?
| | Base Sequence | 1 | 2022 | 2181 | 0.150 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 209 | 0.150 |
Why?
| | Cell Hypoxia | 1 | 2020 | 226 | 0.150 |
Why?
| | Biofilms | 2 | 2019 | 260 | 0.150 |
Why?
| | Exons | 1 | 2020 | 355 | 0.150 |
Why?
| | Medulloblastoma | 1 | 2021 | 193 | 0.150 |
Why?
| | Computer Communication Networks | 1 | 2018 | 33 | 0.150 |
Why?
| | Gene Expression Regulation | 3 | 2018 | 2607 | 0.150 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 325 | 0.150 |
Why?
| | DNA Repair | 2 | 2011 | 231 | 0.150 |
Why?
| | Pseudomonas fluorescens | 1 | 2018 | 3 | 0.150 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2019 | 528 | 0.150 |
Why?
| | Proteins | 2 | 2016 | 1009 | 0.140 |
Why?
| | Alternative Splicing | 1 | 2020 | 229 | 0.140 |
Why?
| | Atlases as Topic | 1 | 2018 | 10 | 0.140 |
Why?
| | Sex Factors | 1 | 2024 | 2071 | 0.140 |
Why?
| | Down Syndrome | 1 | 2025 | 496 | 0.140 |
Why?
| | Hypertension | 2 | 2019 | 1295 | 0.140 |
Why?
| | Recombinational DNA Repair | 1 | 2018 | 16 | 0.140 |
Why?
| | Cyclic GMP | 1 | 2018 | 93 | 0.140 |
Why?
| | Biomarkers, Tumor | 1 | 2025 | 1276 | 0.140 |
Why?
| | Pennsylvania | 1 | 2018 | 116 | 0.140 |
Why?
| | Bone and Bones | 1 | 2021 | 317 | 0.140 |
Why?
| | Immunity, Cellular | 1 | 2019 | 268 | 0.140 |
Why?
| | Glomerulonephritis | 1 | 2018 | 47 | 0.140 |
Why?
| | False Positive Reactions | 1 | 2018 | 115 | 0.140 |
Why?
| | Public Sector | 1 | 2017 | 18 | 0.140 |
Why?
| | Central Nervous System Neoplasms | 1 | 2019 | 156 | 0.140 |
Why?
| | Starvation | 1 | 2017 | 22 | 0.140 |
Why?
| | Trans-Activators | 1 | 2020 | 398 | 0.130 |
Why?
| | Phosphoproteins | 1 | 2019 | 338 | 0.130 |
Why?
| | Metabolic Networks and Pathways | 1 | 2018 | 180 | 0.130 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 606 | 0.130 |
Why?
| | Drug Design | 1 | 2018 | 167 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 434 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 697 | 0.130 |
Why?
| | Multiple Myeloma | 1 | 2019 | 252 | 0.130 |
Why?
| | Information Storage and Retrieval | 1 | 2017 | 118 | 0.130 |
Why?
| | Data Collection | 1 | 2019 | 673 | 0.130 |
Why?
| | Amygdala | 1 | 2017 | 191 | 0.130 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 289 | 0.130 |
Why?
| | Genome, Microbial | 1 | 2016 | 7 | 0.120 |
Why?
| | Body Mass Index | 1 | 2025 | 2389 | 0.120 |
Why?
| | Microbial Consortia | 1 | 2016 | 18 | 0.120 |
Why?
| | Phylogeny | 1 | 2020 | 904 | 0.120 |
Why?
| | Liver Cirrhosis, Biliary | 1 | 2015 | 18 | 0.120 |
Why?
| | Memory | 1 | 2017 | 248 | 0.120 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2018 | 328 | 0.120 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2018 | 767 | 0.120 |
Why?
| | Drug Repositioning | 1 | 2015 | 35 | 0.120 |
Why?
| | Antihypertensive Agents | 1 | 2019 | 494 | 0.120 |
Why?
| | Structure-Activity Relationship | 1 | 2016 | 570 | 0.120 |
Why?
| | Social Behavior | 1 | 2017 | 287 | 0.120 |
Why?
| | Toxicology | 1 | 2015 | 48 | 0.120 |
Why?
| | Search Engine | 1 | 2015 | 12 | 0.120 |
Why?
| | Blood Pressure | 2 | 2019 | 1786 | 0.110 |
Why?
| | Research Design | 1 | 2021 | 1139 | 0.110 |
Why?
| | Knowledge Bases | 1 | 2015 | 27 | 0.110 |
Why?
| | RNA | 4 | 2024 | 921 | 0.110 |
Why?
| | Metabolome | 1 | 2017 | 350 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2021 | 1164 | 0.110 |
Why?
| | Decision Support Techniques | 1 | 2018 | 421 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2015 | 180 | 0.110 |
Why?
| | Prognosis | 3 | 2021 | 4030 | 0.110 |
Why?
| | Genes | 3 | 2013 | 230 | 0.110 |
Why?
| | Hospital Mortality | 1 | 2018 | 911 | 0.100 |
Why?
| | Circadian Rhythm | 1 | 2017 | 468 | 0.100 |
Why?
| | Biological Phenomena | 1 | 2013 | 4 | 0.100 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2015 | 261 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1477 | 0.100 |
Why?
| | Macrophages | 1 | 2021 | 1547 | 0.100 |
Why?
| | Proteome | 1 | 2017 | 472 | 0.100 |
Why?
| | Podocytes | 1 | 2013 | 69 | 0.100 |
Why?
| | Sequence Analysis, DNA | 3 | 2025 | 812 | 0.100 |
Why?
| | Intensive Care Units | 1 | 2018 | 827 | 0.100 |
Why?
| | Length of Stay | 1 | 2018 | 1215 | 0.100 |
Why?
| | Adult | 8 | 2025 | 37929 | 0.100 |
Why?
| | Brain | 1 | 2024 | 2668 | 0.090 |
Why?
| | Middle Aged | 10 | 2025 | 33479 | 0.090 |
Why?
| | Sensitivity and Specificity | 1 | 2017 | 1946 | 0.090 |
Why?
| | Receptors, Estrogen | 1 | 2015 | 436 | 0.090 |
Why?
| | Cell Lineage | 1 | 2013 | 350 | 0.090 |
Why?
| | Survival Analysis | 1 | 2015 | 1325 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2017 | 660 | 0.090 |
Why?
| | Obesity | 1 | 2025 | 2992 | 0.090 |
Why?
| | Cell Line | 2 | 2017 | 2847 | 0.090 |
Why?
| | Aged | 8 | 2025 | 23961 | 0.090 |
Why?
| | Pediatrics | 1 | 2019 | 1101 | 0.090 |
Why?
| | Decision Making | 1 | 2018 | 900 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2018 | 951 | 0.090 |
Why?
| | Bias | 1 | 2012 | 218 | 0.080 |
Why?
| | Brain Neoplasms | 1 | 2019 | 1238 | 0.080 |
Why?
| | Knowledge | 1 | 2010 | 55 | 0.080 |
Why?
| | Microglia | 2 | 2024 | 251 | 0.080 |
Why?
| | Multifactor Dimensionality Reduction | 1 | 2010 | 2 | 0.080 |
Why?
| | Models, Statistical | 3 | 2020 | 669 | 0.080 |
Why?
| | Memory, Long-Term | 2 | 2019 | 12 | 0.080 |
Why?
| | Transcription Factors | 1 | 2017 | 1719 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2013 | 408 | 0.080 |
Why?
| | Parkinson Disease | 1 | 2015 | 493 | 0.080 |
Why?
| | Rats | 3 | 2013 | 5647 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1329 | 0.070 |
Why?
| | Geography | 1 | 2009 | 200 | 0.070 |
Why?
| | Biopsy | 3 | 2018 | 1129 | 0.070 |
Why?
| | Child | 4 | 2021 | 21935 | 0.070 |
Why?
| | Gene Frequency | 1 | 2009 | 521 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5778 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2015 | 4193 | 0.070 |
Why?
| | United States | 2 | 2021 | 14841 | 0.070 |
Why?
| | Multifactorial Inheritance | 1 | 2008 | 174 | 0.070 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2013 | 617 | 0.070 |
Why?
| | Terminal Repeat Sequences | 1 | 2006 | 17 | 0.060 |
Why?
| | Alleles | 1 | 2009 | 891 | 0.060 |
Why?
| | Cytokines | 2 | 2018 | 2085 | 0.060 |
Why?
| | Retroelements | 1 | 2006 | 48 | 0.060 |
Why?
| | Bone Density | 2 | 2021 | 489 | 0.060 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2025 | 41 | 0.060 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2025 | 44 | 0.060 |
Why?
| | Treatment Outcome | 1 | 2019 | 10811 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2009 | 3556 | 0.060 |
Why?
| | Pilot Projects | 2 | 2022 | 1710 | 0.060 |
Why?
| | Europe | 1 | 2025 | 414 | 0.050 |
Why?
| | Culture Media | 1 | 2024 | 165 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 102 | 0.050 |
Why?
| | Microarray Analysis | 1 | 2023 | 117 | 0.050 |
Why?
| | Metals | 1 | 2024 | 136 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2025 | 549 | 0.050 |
Why?
| | Astrocytes | 1 | 2024 | 210 | 0.050 |
Why?
| | Smoking | 1 | 2010 | 1627 | 0.050 |
Why?
| | Sputum | 1 | 2024 | 311 | 0.050 |
Why?
| | Budgets | 1 | 2021 | 13 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5757 | 0.050 |
Why?
| | Interdisciplinary Research | 1 | 2021 | 27 | 0.050 |
Why?
| | Gene Library | 1 | 2021 | 118 | 0.040 |
Why?
| | Self Report | 1 | 2025 | 827 | 0.040 |
Why?
| | Ephrin-B2 | 1 | 2021 | 47 | 0.040 |
Why?
| | Neurofibroma | 1 | 2020 | 3 | 0.040 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2020 | 12 | 0.040 |
Why?
| | Neurofibroma, Plexiform | 1 | 2020 | 9 | 0.040 |
Why?
| | Osteoblasts | 1 | 2021 | 126 | 0.040 |
Why?
| | DNA, Mitochondrial | 1 | 2021 | 200 | 0.040 |
Why?
| | Genetic Markers | 1 | 2021 | 344 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 404 | 0.040 |
Why?
| | Antigens, CD20 | 1 | 2019 | 29 | 0.040 |
Why?
| | Gene Editing | 1 | 2021 | 80 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2020 | 89 | 0.040 |
Why?
| | Data Accuracy | 1 | 2020 | 65 | 0.040 |
Why?
| | Peripheral Nerves | 1 | 2020 | 65 | 0.040 |
Why?
| | Candida albicans | 1 | 2019 | 54 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2025 | 7635 | 0.040 |
Why?
| | Manuscripts, Medical as Topic | 1 | 2019 | 5 | 0.040 |
Why?
| | Chromosome Mapping | 1 | 2021 | 523 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2020 | 133 | 0.040 |
Why?
| | Genome, Fungal | 1 | 2019 | 40 | 0.040 |
Why?
| | Young Adult | 3 | 2021 | 13209 | 0.040 |
Why?
| | Reward | 1 | 2021 | 244 | 0.040 |
Why?
| | Osteogenesis | 1 | 2021 | 188 | 0.040 |
Why?
| | Osteosarcoma | 1 | 2019 | 74 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 955 | 0.040 |
Why?
| | Rhabdomyosarcoma | 1 | 2019 | 72 | 0.040 |
Why?
| | Locomotion | 1 | 2019 | 106 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2019 | 142 | 0.040 |
Why?
| | Mentoring | 1 | 2021 | 149 | 0.040 |
Why?
| | Wilms Tumor | 1 | 2019 | 86 | 0.040 |
Why?
| | Quantitative Trait Loci | 1 | 2021 | 380 | 0.040 |
Why?
| | Tissue Distribution | 1 | 2019 | 332 | 0.040 |
Why?
| | Neuroblastoma | 1 | 2019 | 160 | 0.040 |
Why?
| | Genes, Neoplasm | 1 | 2018 | 22 | 0.040 |
Why?
| | Sarcoma, Ewing | 1 | 2019 | 97 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 210 | 0.040 |
Why?
| | Two-Hybrid System Techniques | 1 | 2018 | 59 | 0.040 |
Why?
| | Pentose Phosphate Pathway | 1 | 2018 | 53 | 0.040 |
Why?
| | Loss of Heterozygosity | 1 | 2018 | 51 | 0.040 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2018 | 23 | 0.040 |
Why?
| | Bacteria | 1 | 2025 | 858 | 0.040 |
Why?
| | Monocytes | 1 | 2021 | 563 | 0.040 |
Why?
| | Nephrotic Syndrome | 1 | 2018 | 39 | 0.040 |
Why?
| | Acid Phosphatase | 1 | 2017 | 20 | 0.030 |
Why?
| | MAP Kinase Signaling System | 1 | 2019 | 320 | 0.030 |
Why?
| | Mobile Applications | 1 | 2020 | 183 | 0.030 |
Why?
| | Mouth | 1 | 2017 | 87 | 0.030 |
Why?
| | Kidney Glomerulus | 1 | 2018 | 119 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2020 | 465 | 0.030 |
Why?
| | Kidney Tubules | 1 | 2018 | 117 | 0.030 |
Why?
| | Patient Care Planning | 1 | 2018 | 157 | 0.030 |
Why?
| | Isoenzymes | 1 | 2018 | 304 | 0.030 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 2017 | 91 | 0.030 |
Why?
| | GTPase-Activating Proteins | 1 | 2017 | 83 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2018 | 133 | 0.030 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2017 | 98 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 422 | 0.030 |
Why?
| | Chromatin | 1 | 2021 | 519 | 0.030 |
Why?
| | Motivation | 1 | 2021 | 570 | 0.030 |
Why?
| | Recurrence | 1 | 2019 | 1060 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 967 | 0.030 |
Why?
| | Databases, Protein | 1 | 2016 | 85 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1972 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2021 | 1250 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2016 | 78 | 0.030 |
Why?
| | Saliva | 1 | 2017 | 242 | 0.030 |
Why?
| | Biopsy, Fine-Needle | 1 | 2016 | 68 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2018 | 366 | 0.030 |
Why?
| | Genetic Loci | 1 | 2017 | 288 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2021 | 712 | 0.030 |
Why?
| | Blood Proteins | 1 | 2017 | 252 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 739 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 327 | 0.030 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2018 | 242 | 0.030 |
Why?
| | Hydrocortisone | 1 | 2017 | 322 | 0.030 |
Why?
| | DNA Damage | 1 | 2018 | 420 | 0.030 |
Why?
| | Transforming Growth Factor beta | 1 | 2018 | 480 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 792 | 0.030 |
Why?
| | Oxygen | 1 | 2020 | 931 | 0.030 |
Why?
| | Risk Factors | 1 | 2009 | 10388 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2074 | 0.030 |
Why?
| | Esophagus | 1 | 2017 | 255 | 0.030 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 900 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1050 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1457 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2016 | 601 | 0.030 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 558 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2019 | 860 | 0.030 |
Why?
| | Aging | 1 | 2024 | 1864 | 0.030 |
Why?
| | Heart Rate | 1 | 2017 | 822 | 0.030 |
Why?
| | Colorado | 1 | 2024 | 4565 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 916 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2016 | 658 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2021 | 2475 | 0.030 |
Why?
| | Regression Analysis | 1 | 2015 | 1024 | 0.030 |
Why?
| | Support Vector Machine | 1 | 2013 | 38 | 0.030 |
Why?
| | Organogenesis | 1 | 2013 | 58 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2020 | 2844 | 0.020 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 167 | 0.020 |
Why?
| | Nanotechnology | 1 | 2013 | 125 | 0.020 |
Why?
| | Computer Graphics | 1 | 2012 | 42 | 0.020 |
Why?
| | Skin | 1 | 2017 | 752 | 0.020 |
Why?
| | Risk | 1 | 2015 | 912 | 0.020 |
Why?
| | Apoptosis | 1 | 2021 | 2553 | 0.020 |
Why?
| | Adolescent | 2 | 2021 | 21513 | 0.020 |
Why?
| | Drug Interactions | 1 | 2013 | 410 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 528 | 0.020 |
Why?
| | Genetic Variation | 1 | 2015 | 991 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2018 | 2833 | 0.020 |
Why?
| | Caenorhabditis elegans | 1 | 2013 | 306 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5472 | 0.020 |
Why?
| | Zebrafish Proteins | 1 | 2012 | 288 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4295 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2012 | 427 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 499 | 0.020 |
Why?
| | Curriculum | 1 | 2015 | 992 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2015 | 1043 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6828 | 0.020 |
Why?
| | Child, Preschool | 1 | 2021 | 11074 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2013 | 1991 | 0.020 |
Why?
| | Lung | 1 | 2017 | 4060 | 0.010 |
Why?
| | Inflammation | 1 | 2015 | 2837 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 2015 | 2526 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2018 | 15657 | 0.010 |
Why?
|
|
Greene's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|